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ABSTRACT  
B lymphoblastic leukemia (B-ALL) may be associated with recurrent cytogenetic and molecular abnormalities.  
We describe the fourth-known case of B-ALL associated with the t(8;22)(p11.2q11.2) – a translocation seen 
more frequently in T lymphoblastic leukemia and acute myelogenous leukemia.  This patient’s leukemia involves 
a combination of additional cytogenetic anomalies not yet described in the literature, including del(11)(q13q23), 
add(9)(p22), and monosomy 7.  Given the role in B cell differentiation of genes in the affected regions, including 
MEN1 (11q13), ATM (11q22), ETS1(11q23), MLL (11q23), AF9 (9p22), and IKZ-F1 (7p12), this case may provide 
further insight into B cell leukemogenesis associated with the t(8;22).  Deletion or mutation of these genes may 
be critical in targeting the B cell population, and this cytogenetic profile of a B-ALL suggests additional gene 
targets for diagnostic and therapeutic consideration. 
INTRODUCTION 
 B cell acute lymphoblastic leukemia (B-ALL) 
may be associated with recurrent cytogenetic and 
molecular abnormalities.  We describe the fourth-
known case of B-ALL associated with the 
t(8;22)(p11.2q11.2) [1-3].  In addition, this B-ALL 
has associated cytogenetic anomalies not yet 
described in the literature; a del(11)(q13q23), an 
add(9)(p22), and a monosomy 7 were also 
present.  Important gene groups for B cell 
differentiation were identified on these 
chromosomes, which may provide further insight 
into B cell leukemogenesis associated with the 
t(8;22). 
 
CASE REPORT 
 The patient, a 78-year-old woman, 
presented with a two-week history of chest pain, 
shortness of breath, and severe abdominal pain 
with accompanying nausea and night sweats.  The 
complete blood count (CBC) revealed a 
leukocytosis and thrombocytopenia [white blood 
cell count (WBC) 70.93x10^3/ul and platelets 
13x10^3/uL] as well as anemia (hemoglobin 
9.7g/dL and hematocrit 29.5%).  Evaluation of the 
peripheral blood smear revealed 60% blasts.  The 
blasts on the peripheral smear were intermediate 
in size with a high nuclear/cytoplasmic ratio, ovoid 
to irregular nuclei with fine chromatin, and with 
inconspicuous nucleoli and scant blue cytoplasm 
(Fig 1A). 
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Figure 1: Blast cells in peripheral blood: Wright-Giemsa stain, 
50x (A).  Bone marrow aspirate: Wright-Giemsa stain, 50x 
(B,C).  Bone marrow: hematoxylin and eosin stain, 40x (D), 
mitotic figure of leukemic blast, hematoxylin and eosin 
stain,100x (D inset). 
 Approximately 90-100% of the cells in the 
bone marrow aspirate were blasts similar to those 
observed in the peripheral blood (Fig 1B,C). The 
bone marrow biopsy was hypercellular (90-100%) 
with a monotonous infiltrate of blasts with 
frequent mitotic figures (Fig 1D). Flow cytometric 
analysis of the peripheral blood revealed a blast 
population that was CD 10, 19, 20, 33, 34 and 
HLA-DR positive, consistent with B-ALL.  
Immunohistochemical staining of the bone 
marrow core biopsy confirmed a population of 
CD34, CD10, CD79a and CD20 positive cells (Fig 2). 
 
Figure 2: Immunohistochemical staining of the bone marrow 
core biopsy: CD10 (A), CD20 (B), CD34 (C), CD79a (D). (All at 
20x.)  
 Cytogenetic analysis revealed a 
t(8;22)(p11.2;q11.2) in all metaphases analyzed.  
In addition to the translocation, 30% of this cell 
population had additional chromosomal 
abnormalities, including del(11)(q13q23), 
add(9)(p22) and monosomy 7.  FISH showed no 
fusion of ETV6 (TEL; 12p13) and RUNX1 AML1; 
21q22) regions. The patient received Rituximab, to 
which she had an anaphylactic reaction.  She 
refused further chemotherapy and was lost to 
follow-up. 
DISCUSSION 
 B-ALL is a neoplasm of lymphoblasts 
committed to the B-cell lineage.  The genetic 
profile of the blasts is of critical importance 
regarding prognosis and therapeutic management 
of the leukemic process.  Considering this, the 
World Health Organization has classified certain 
subgroups of B-ALL according to the chromosomal 
translocation expressed by the malignant 
population of cells.  There are several such 
translocations commonly associated with B-ALL, 
such as such as t(9;22) and t(12;21).  These 
translocations produce identifiable fusion 
proteins, the downstream affects of which are 
thought to influence features of this leukemia.  
Whereas this has been helpful for estimating 
patient outcome and determining treatment 
regimen, it does not necessarily provide reliable 
insight into the initial steps of leukemogenesis. 
The translocation associated with a lesion may be 
sufficient to drive cancer pathogenesis, but a 
direct correlation between translocation 
expressed and the leukemia it produces is 
inconsistent [4].  This suggests that along with the 
chromosomal translocation, additional genetic 
mechanisms are involved in determining which 
blast population is affected and at which stage the 
cells are arrested. 
 The translocation t(8;22)(p11.2q11.2) has 
been shown to produce a fusion protein, 
combining regions of the gene coding for 
fibroblast growth factor receptor 1 (FGFR1) with 
regions of the gene coding for breakpoint cluster 
region (BCR). Constitutive activation of the FGFR1 
kinase region is generated by the relocation of this 
region to a location downstream of the BCR region 
in t(8;22)(p11.2q11.2).  The activity of this fusion 
protein has been previously shown to arrest the 
neoplastic population at an early B-cell stage [5].  
In addition, it allows this population to proliferate 
in a cytokine independent manner [6] conferring 
oncogenic potential. The mechanisms underlying 
these capabilities have yet to be fully elucidated, 
but studies have identified some aspects of the 
molecular activity. For example, the BCR-FGFR1 
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protein has been shown to constitutively activate 
STAT5, which may underlie the cytokine 
independence of the cells and the subsequent 
ability of this population to survive and expand 
[7]. 
 Despite this evidence that BCR-FGFR1 has 
the ability to manifest in a B-cell population, the 
diagnosis in the majority of reported cases with 
the translocation producing this fusion protein has 
clinical features that resemble chronic 
myelogenous leukemia (CML).  This disease is 
aggressive and rapidly evolves to acute 
myelogenous leukemia (AML) or less commonly to 
T lymphoblastic leukemia (T-ALL).  Understanding 
the leukemogenesis in this case of B-ALL, then, 
necessitates a closer look at the other cytogenetic 
anomalies identified in the blast population and 
their potential contribution to the actions of the 
BCR-FGFR1 fusion protein.   
 Here, we consider the cytogenetic profile of 
the presented case.  In addition to the 
t(8;22)(p11.2;q11.2) karyotype, 30% of the cells 
revealed three additional chromosomal 
abnormalities, del(11)(q13q23), add(9)(p22) and 
monosomy 7.  Each of these affected regions 
harbors genes that participate in normal B cell 
development, and deletion or mutation within 
these gene regions may therefore have 
implications in the pathogenesis or progression of 
this B cell leukemic process.  Within the region of 
the 11q deletion, there are several candidate 
genes including MEN1 (11q13), ATM (11q22), 
ETS1(11q23), and MLL (11q23) that have been 
shown to play critical roles in B cell differentiation. 
 The MEN1 gene codes for menin, a protein 
involved in regulation of B lymphoid progenitor 
differentiation by regulating Hoxa9 expression. 
Loss of menin function has been associated with 
impaired B lymphoid progenitor development.  In 
addition, the interaction of menin with MLL fusion 
proteins is well-documented and may be of 
interest in our case, as MLL is also within the 
region of the 11q deletion. The MLL protein is an 
important component of hematopoiesis -- it acts 
as part of a complex of proteins that also includes 
menin to dictate cell fate of progenitor cells 
through Hox gene expression regulation [8].  
Disruption of the MLL gene at 11q23 is 
characteristic of well-recognized subsets of acute 
leukemia, often associated with blast cells that 
generate MLL fusion proteins.  The blast 
populations produced are arrested at an early 
progenitor stage and proliferate in response to 
increased levels of Hox9, itself driven by MLL 
fusion proteins.  MLL translocation can be cryptic, 
often presenting as an 11q23 deletion, detectable 
only if further studies are performed, such as 
multiplex FISH analysis [9].  Additional analysis 
was not performed in this case; however, 
especially with the finding of addition at 9p22 
harboring AF9, a frequent MLL fusion partner, 
identification of MLL translocation in this cell 
population may have had implications for 
diagnosis and treatment.    
 ATM, ETS1 and IKZ-F1 gene deletions have 
also been linked to leukemic B-cell 
transformation.  Deletion of these genes interfere 
with pre-B cell receptor function, inhibiting 
signaling that is critical to induce the switch from 
early B cell proliferation to differentiation [10-12].  
Of note and relevant to the monosomy 7 present 
in the current report, IKZ-F1(7p12.2) may be 
particularly important in targeting B-cells for 
transformation to leukemia.  IKZ-F1 codes for 
Ikaros, a protein that is required for the ability of 
the pre-B cell receptor to induce B-cell 
differentiation, possibly through activation of SLP-
65.  Deficiency of SLP-65 has been linked to pre-B 
cell proliferation and pre-B-cell leukemogenesis.  
The applicability of this information may be 
further clarified through consideration of recent 
data examining mechanisms underlying BCR-ABL 
positive B-ALL.  BCR-ABL+ leukemia most often 
manifests as a chronic myelogenous leukemia.  
However, recent data comparing the complete 
cytogenetic profiles of BCR-ABL B-ALL and BCR-
ABL CML has revealed the presence of an IKZ-F1 
mutation in 84% of BCR-ABL- induced B-ALL, a 
mutation not seen in the myelogenous leukemia 
type with this fusion protein. The literature on 
BCR-FGFR1-induced B-ALL is comparatively sparse. 
However, Baldazzi et al also described monosomy 
7 as part of the cytogenetic profile in their case 
report of B-ALL with a t(8;22)(p11.2q11.2) [1]. 
CONCLUSION 
 Our case suggests that the mechanism of B-
ALL with t(8;22)(p11.2q11.2) is multifactorial. This 
particular cytogenetic profile of B-ALL suggests 
additional gene targets for diagnostic and 
therapeutic consideration.  In addition, alteration 
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of genes critical for B cell differentiation provides 
insight into how the 8;22 translocation, more 
commonly seen in myelogenous as well as T cell 
leukemia, may also be associated with disruptions 
in B cell leukemogenesis. 
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